BCL11A enhances stemness and promotes progression by activating Wnt/β-catenin signaling in breast cancer

References

• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–768. doi:10.1038/nrc249918784658
   PubMed Web of Science ®Google Scholar
• Grotenhuis BA, Wijnhoven BP, van Lanschot JJ. Cancer stem cells and their potential implications for the treatment of solid tumors. J Surg Oncol. 2012;106:209–215. doi:10.1002/jso.2306922371125
   PubMed Web of Science ®Google Scholar
• Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18:460–466. doi:10.1016/j.copbio.2007.10.00718023337
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. doi:10.1038/3510216711689955
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. doi:10.1073/pnas.053029110012629218
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106:13820–13825. doi:10.1073/pnas.090571810619666588
   PubMed Web of Science ®Google Scholar
• Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15:4234–4241. doi:10.1158/1078-0432.CCR-08-147919509181
   PubMed Web of Science ®Google Scholar
• Shafee N, Smith CR, Wei S, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008;68:3243–3250. doi:10.1158/0008-5472.CAN-07-548018451150
   PubMed Web of Science ®Google Scholar
• Lazarus KA, Hadi F, Zambon E, et al. BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. Nat Commun. 2018;9:3327. doi:10.1038/s41467-018-05790-530127402
   PubMed Web of Science ®Google Scholar
• Jiang BY, Zhang XC, Su J, et al. BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. Mol Cancer. 2013;12:61. doi:10.1186/1476-4598-12-6123758992
   PubMed Web of Science ®Google Scholar
• Khaled WT, Choon Lee S, Stingl J, et al. BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. Nat Commun. 2015;6:5987. doi:10.1038/ncomms698725574598
   PubMed Web of Science ®Google Scholar
• Moody RR, Lo MC, Meagher JL, et al. Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem. 2018;293:2125–2136. doi:10.1074/jbc.M117.81146329263092
   PubMed Web of Science ®Google Scholar
• Smith EC, Luc S, Croney DM, et al. Strict in vivo specificity of the Bcl11a erythroid enhancer. Blood. 2016;128:2338–2342. doi:10.1182/blood-2016-08-73624927707736
   PubMed Web of Science ®Google Scholar
• Lv C, Li F, Li X, et al. MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. Nat Commun. 2017;8:1036. doi:10.1038/s41467-017-01059-529051494
   PubMed Web of Science ®Google Scholar
• Huang X, Borgstrom B, Stegmayr J, et al. The molecular basis for inhibition of stemlike cancer cells by Salinomycin. ACS Cent Sci. 2018;4:760–767. doi:10.1021/acscentsci.8b0025729974072
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429–1437. doi:10.1172/JCI3618319487819
   PubMed Web of Science ®Google Scholar
• Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development. 2012;139:3471–3486. doi:10.1242/dev.07120922949611
   PubMed Web of Science ®Google Scholar
• Tang H, Deng M, Tang Y, et al. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clin Cancer Res. 2013;19:5602–5612. doi:10.1158/1078-0432.CCR-13-132623995857
   PubMed Web of Science ®Google Scholar
• Yang L, Tang H, Kong Y, et al. LGR5 promotes breast cancer progression and maintains stem-like cells through activation of Wnt/beta-catenin signaling. Stem Cells. 2015;33:2913–2924. doi:10.1002/stem.208326086949
   PubMed Web of Science ®Google Scholar
• Luc S, Huang J, McEldoon JL, et al. Bcl11a deficiency leads to hematopoietic stem cell defects with an aging-like phenotype. Cell Rep. 2016;16:3181–3194. doi:10.1016/j.celrep.2016.08.06427653684
   PubMed Web of Science ®Google Scholar
• Chen B, Wei W, Huang X, et al. circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. Theranostics. 2018;8:4003–4015. doi:10.7150/thno.2410630083277
   PubMed Web of Science ®Google Scholar
• Chen F, Luo N, Hu Y, Li X, Zhang K. MiR-137 suppresses triple-negative breast cancer stemness and tumorigenesis by perturbing BCL11A-DNMT1 interaction. Cell Physiol Biochem. 2018;47:2147–2158. doi:10.1159/00049152629975921
   PubMedGoogle Scholar
• Yin J, Zhang F, Tao H, et al. BCL11A expression in acute phase chronic myeloid leukemia. Leuk Res. 2016;47:88–92. doi:10.1016/j.leukres.2016.05.01827285855
   PubMed Web of Science ®Google Scholar
• Zhou J, Yang Y, Zhang D, Zhou L, Tao L, Lu LM. Genetic polymorphisms and plasma levels of BCL11A contribute to the development of laryngeal squamous cell carcinoma. PLoS One. 2017;12:e0171116. doi:10.1371/journal.pone.017111628225775
   PubMed Web of Science ®Google Scholar
• Satterwhite E, Sonoki T, Willis TG, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 2001;98:3413–3420.11719382
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang J, Khaled W, et al. Bcl11a is essential for lymphoid development and negatively regulates p53. J Exp Med. 2012;209:2467–2483. doi:10.1084/jem.2012184623230003
   PubMed Web of Science ®Google Scholar
• Trimboli AJ, Fukino K, de Bruin A, et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res. 2008;68:937–945. doi:10.1158/0008-5472.CAN-07-214818245497
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–454. doi:10.1038/nrc82212189386
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai). 2008;40:643–650.18604456
   PubMed Web of Science ®Google Scholar
• Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–558. doi:10.1016/j.ceb.2005.08.00116098727
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717–728. doi:10.1016/j.stem.2012.05.00722704512
   PubMed Web of Science ®Google Scholar
• Clevers H, Loh KM, Nusse R; Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science (New York, NY). 2014;346:1248012. doi:10.1126/science.1248012
   Google Scholar